1 |
Choi SY, Kim CH, Sohn DW, et al., Clinical characteristics and management in elderly patients with atrial fibrillation. J Korean Geriatr Soc 1999; 3: 82-90.
|
2 |
Ansell J, Hirsh J, Hylek E, et al., Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th edition. Chest 2008; 133: 160S-198S.
DOI
|
3 |
Hylek EM, Go AS, Chang Y, et al., Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. N Engl J Med 2003; 349:1019-26.
DOI
|
4 |
Pautas E, Moreau C, Gouin-Thibault I, et al., Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010; 87: 57-64.
DOI
|
5 |
Perez-Andreu V, Roldan V, Anton AI, et al., Pharmacogenetic relevance of CYP4F2V433M polymorphism on acenocoumarol therapy. Blood 2009; 113: 4977-9.
DOI
|
6 |
Shikata E, Ieiri I, Ishiguro S, et al., Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factor II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 2630-5.
DOI
|
7 |
Product information. Coumadin (warfarin). Bristol-Myers Squibb; Princeton, NJ: 2010.
|
8 |
Takamura N, Haruta A, Kodama H, et al., Mode of interaction of loop diuretics with human serum albumin and characterization of binding site. Pharm Res 1996; 13: 1015-9.
DOI
|
9 |
O'Reilly RA, Sahud MA, Aggeler PM, et al., Impact of aspirin and chlorthalidone on the pharmacodynamics of oral anticoagulant drugs in man. Ann NY Acad Sci 1971; 179: 173-86.
DOI
|
10 |
Laizure SC, Madlock L, Cyr M, et al., Decreased hypoprothrombinemic effect of warfarin associated with furosemide. Ther Drug Monit 1997; 19: 361-3.
DOI
|
11 |
Bird J, Carmona C. Probable interaction between warfarin and torsemide. Ann Pharmacother 2008; 42: 1893-8.
DOI
|
12 |
Trewin VF. A probable interaction between warfarin and metolazone. Pharm J 1988; 240: 781-2.
|
13 |
Nilsson CM, Horton ES, Robinson DS, et al., The effect of furosemide and bumetanide on warfarin metabolism and anticoagulant response. J Clin Pharmacol 1978; 18: 91-4.
DOI
|
14 |
Nipper H, Kirby S, Iber FL. The effect of bumetanide on the serum disappearance of warfarin sodium. J Clin Pharmacol 1981; 21: 654-6.
DOI
|
15 |
O'Reilly RA. Spironolactone and warfarin interaction. Clin Pharmacol Ther 1980; 27: 198-201.
DOI
|
16 |
Heather D, Ryan D, Susan E, et al., Effect of oral diuretics on chronic warfarin therapy: retrospective study. Expert Opinion on Drug Safety 2012; 11: 375-380.
DOI
|
17 |
Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007; 2: 93-106.
DOI
|
18 |
Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trend Pharmacol Sci 2009; 30: 375-86.
DOI
|
19 |
Lee KE, Chang BC, Kim HO, et al., Effects of CYP4F2 Gene Polymorphisms on Warfarin Clearance and Sensitivity in Korean Patients With Mechanical Cardiac Valves. Ther Drug Monit 2012; 34: 275-82.
DOI
|
20 |
Garcia D, Regan S, Crowther M, et al., Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005; 127: 2049-56.
DOI
|
21 |
O'Connell MB, Kowal PR, Allivato CJ, et al., Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 2000; 20: 923-30.
DOI
|
22 |
Micromedex. Available from: www. thomsonhc.com [Last accessed 25 June 2012].
|